368 related articles for article (PubMed ID: 23236213)
21. The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition.
Bakkour A; Morris JC; Wolk DA; Dickerson BC
Neuroimage; 2013 Aug; 76():332-44. PubMed ID: 23507382
[TBL] [Abstract][Full Text] [Related]
22. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
23. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia.
Bakkour A; Morris JC; Dickerson BC
Neurology; 2009 Mar; 72(12):1048-55. PubMed ID: 19109536
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
25. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
26. Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
Hayes JP; Logue MW; Sadeh N; Spielberg JM; Verfaellie M; Hayes SM; Reagan A; Salat DH; Wolf EJ; McGlinchey RE; Milberg WP; Stone A; Schichman SA; Miller MW
Brain; 2017 Mar; 140(3):813-825. PubMed ID: 28077398
[TBL] [Abstract][Full Text] [Related]
27. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults.
Dickerson BC; Wolk DA;
Neurology; 2012 Jan; 78(2):84-90. PubMed ID: 22189451
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
[TBL] [Abstract][Full Text] [Related]
29. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
[TBL] [Abstract][Full Text] [Related]
30. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
Fjell AM; Walhovd KB; Fennema-Notestine C; McEvoy LK; Hagler DJ; Holland D; Brewer JB; Dale AM;
J Neurosci; 2010 Feb; 30(6):2088-101. PubMed ID: 20147537
[TBL] [Abstract][Full Text] [Related]
31. The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis.
Scheltens NM; Galindo-Garre F; Pijnenburg YA; van der Vlies AE; Smits LL; Koene T; Teunissen CE; Barkhof F; Wattjes MP; Scheltens P; van der Flier WM
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):235-43. PubMed ID: 25783437
[TBL] [Abstract][Full Text] [Related]
32. Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Waragai M; Hata S; Suzuki T; Ishii R; Fujii C; Tokuda T; Arai H; Ohrui T; Higuchi S; Yoshida M; Igarashi K; Moriya M; Iwai N; Uemura K
J Alzheimers Dis; 2014; 41(4):1207-22. PubMed ID: 24787913
[TBL] [Abstract][Full Text] [Related]
33. Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults.
Wennberg AM; Spira AP; Pettigrew C; Soldan A; Zipunnikov V; Rebok GW; Roses AD; Lutz MW; Miller MM; Thambisetty M; Albert MS
J Neurol Sci; 2016 Jun; 365():89-95. PubMed ID: 27206882
[TBL] [Abstract][Full Text] [Related]
34. Subthreshold Amyloid Predicts Tau Deposition in Aging.
Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
[TBL] [Abstract][Full Text] [Related]
36. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
37. Sex differences in the association between AD biomarkers and cognitive decline.
Koran MEI; Wagener M; Hohman TJ;
Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
[TBL] [Abstract][Full Text] [Related]
38. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.
Maass A; Lockhart SN; Harrison TM; Bell RK; Mellinger T; Swinnerton K; Baker SL; Rabinovici GD; Jagust WJ
J Neurosci; 2018 Jan; 38(3):530-543. PubMed ID: 29192126
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer's disease.
Reas ET; Hagler DJ; White NS; Kuperman JM; Bartsch H; Cross K; Loi RQ; Balachandra AR; Meloy MJ; Wierenga CE; Galasko D; Brewer JB; Dale AM; McEvoy LK
Alzheimers Res Ther; 2017 Aug; 9(1):55. PubMed ID: 28764771
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
